Alcresta Therapeutics Financing
Alcresta Therapeutics, Inc., Corporation just released form D about $50.89 million equity financing. The date of first sale was 2016-03-22. Alcresta Therapeutics was able to finance itself with $50.89 million. That is 100.00% of the fundraising. The total private offering amount was $50.89 million. The private financing document was filed on 2016-10-31. The reason for the financing was: Total amount offered and sold include securities sold in connection with the conversion of convertible promissory notes..
Alcresta Therapeutics is based in Massachusetts. The company’s business is Biotechnology. The SEC form was filed by Tasos Konidaris Chief Financial Officer. The company was incorporated in 2011. The filler’s address is: One Newton Executive Park, Suite 100, Newton, Ma, Massachusetts, 02462. Daniel Tasse is the related person in the form and it has address: One Newton Executive Park, Suite 100, Newton, Ma, Massachusetts, 02462. Link to Alcresta Therapeutics Filing: 000114036116084182.
Analysis of Alcresta Therapeutics Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Alcresta Therapeutics sold 100.00% of the offering. Could this mean that the trust in Alcresta Therapeutics is high? The average offering amount for companies in the Biotechnology industry is $3.08 million. The total amount raised is 1,552.26% bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Alcresta Therapeutics Also
The Form D signed by Tasos Konidaris might help Alcresta Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.